Tumour‑infiltrating lymphocyte (TIL) therapy has demonstrated tremendous promise in the treatment of solid cancers by harnessing a patient’s own tumor‑reactive immune cells to drive targeted anti‑tumor responses. In a major clinical milestone, the FDA approval of the first TIL therapy in 2024 — representing the first cellular therapy approved for a solid tumour (advanced melanoma) — has catalyzed renewed interest and momentum in this field.
Join us for an engaging virtual panel bringing together a clinician with industry experience in the TIL space, a patient who has undergone TIL therapy, and a cell manufacturing expert. Together, they will explore the clinical significance of this advancement, its real-world impact on patients, and the evolving landscape of care. The discussion will also highlight advances in TIL manufacturing and scalability, examine the challenges and opportunities in integrating TIL therapy into clinical practice, and consider future directions, including expanding applications beyond melanoma to other solid tumour indications.